Search
Clobetasol
go.drugbank.com/drugs/DB11750ApprovedInvestigationalWithdrawnClobetasol has been investigated for the prevention of Psoriasis and Cutaneous Atrophy Due to Corticosteroids.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersScorpion (centruroides) immune Fab2 antivenin (equine)
go.drugbank.com/drugs/DB13905ApprovedEnvenomation by a scorpion sting can result in serious cardiovascular effects [A32483]. … Most commonly, children experience severe reactions, however, adults can be affected, too [L2195], [L2196], [L2198].
Citrus bioflavonoids
go.drugbank.com/drugs/DB14586ApprovedMixtures: Rose Hips 500plus Nu Life, Bioflavonoids With Rose Hips C Nu LifeGalidesivir
go.drugbank.com/drugs/DB11676InvestigationalGalidesivir is an adenosine analogue that has been investigated for use against Zaire Ebolavirus.
Ceftobiprole medocaril
go.drugbank.com/drugs/DB14733ApprovedMedicinal Products for Human Use (CHMP) adopted a negative opinion of ceftobiprole medocaril in February 2010, recommending the refusal of its marketing authorization in the European Union primarily due
X-376
go.drugbank.com/drugs/DB13104InvestigationalX-376 is an inhibitor of the anaplastic lymphoma kinase (ALK) which can penetrate the blood brain barrier.[A265085]
Trapidil
go.drugbank.com/drugs/DB09283ExperimentalTrapidil, a platelet-derived growth factor antagonist, was originally developed as a vasodilator and anti-platelet agent and has been used to treat patients with ischemic coronary heart, liver, and kidney disease.
Mivacurium
go.drugbank.com/drugs/DB01226ApprovedWithdrawnMivacurium is a bisbenzylisoquinolinium based neuromuscular blocker or muscle relaxant. It binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscul...
Ingenol mebutate
go.drugbank.com/drugs/DB05013ApprovedWithdrawnBefore approval, ingenol mebutate was called PEP005 as an investigational drug.
Synonyms: Mebutato de ingenolNerandomilast
go.drugbank.com/drugs/DB18237ApprovedInvestigational[L54126] Compared to pan-PDE4 inhibitors, selective PDE4B inhibitors are associated with a lower potential for gastrointestinal adverse events.[A274581] On December 19, 2025, the U.S.
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors